The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma

The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma

Background: Neuroblastoma is a deadly childhood cancer, and MYCN-amplified neuroblastoma (MNA-NB) patients have the worst prognoses and are therapy-resistant. While retinoic acid (RA) is beneficial for some neuroblastoma patients, the cause of RA resistance is unknown. Thus, there remains a need for...

Full description

Bibliographic Details
Main Authors: Amadesi, C. (Author), Angelucci, S. (Author), Bartolucci, D. (Author), Bortolotti, S. (Author), Cerisoli, L. (Author), Fischer, M. (Author), Hrelia, P. (Author), Lampis, S. (Author), Martelli, A.M (Author), Montemurro, L. (Author), Nieddu, G. (Author), Paganelli, F. (Author), Pasquinelli, G. (Author), Pession, A. (Author), Raieli, S. (Author), Scardovi, A.L (Author), Tonelli, R. (Author), Valente, S. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
Differentiation
mTOR pathway
MYCN
Neuroblastoma
Retinoic acid resistance
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items